SomaLogic Inc.’s SLGC stock was up about 12% in premarket trades on Wednesday after the Boulder, Colo.-based specialist in cell proteins agreed to be acquired in an all-stock merger with Standard ...

Detailed price information for Standard Biotools Inc (LAB-Q) from The Globe and Mail including charting and trades.

KeyBanc Capital Markets initiated coverage on Standard BioTools Inc (NASDAQ:LAB) with an Overweight rating and a price target of $4. The analyst says Standard BioTools is a unique and attractively ...

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction ...

CEO Michael Egholm highlighted that Standard BioTools delivered Q1 2025 revenues of $40.8 million, aligned with their plan despite a challenging operating backdrop. He emphasized improvements in ...

The Dow Jones index closed higher by around 0.2% on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders ...

Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at ...

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (LAB) (Standard BioTools or the Company), driven by a bold purpose – Unleashing tools to accelerate breakthroughs ...

We firmly believe that the value-maximizing transaction with Standard BioTools is the best path forward for SomaLogic and all of its stockholders. You have an essential decision to make regarding the ...

Illumina said the acquisition of SomaLogic will bolster its multiomics strategy to move beyond DNA sequencing, while Standard BioTools said the turnaround sale gives it an opportunity to break even ...